Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Friedman

Showing results (1431-1440 of 1,475) with videos related to

Pageof 148
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2005
Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study resultsDavid A Reardon, Gamal Akabani, R Edward Coleman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 1999
Irinotecan therapy in adults with recurrent or progressive malignant gliomaH S Friedman, W P Petros, A H Friedman, et al.
Oncotarget|April 12, 2014
Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomasPatrick J Killela, Christopher J Pirozzi, Patrick Healy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2002
Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomasDavid A Reardon, Gamal Akabani, R Edward Coleman, et al.
Neuro-Oncology|February 22, 2008
A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boostDavid A Reardon, Michael R Zalutsky, Gamal Akabani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 10, 2006
Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant gliomaDavid A Reardon, Jennifer A Quinn, James J Vredenburgh, et al.
Nature Genetics|June 2, 2014
Exome sequencing identifies somatic gain-of-function PPM1D mutations in brainstem gliomasLiwei Zhang, Lee H Chen, Hong Wan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 26, 2003
Phase II trial of gefitinib in recurrent glioblastomaJeremy N Rich, David A Reardon, Terry Peery, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 14, 2000
Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant gliomaH S Friedman, J Pluda, J A Quinn, et al.
Brain Communications|June 6, 2022
Intraoperative microseizure detection using a high-density micro-electrocorticography electrode arrayJames Sun, Katrina Barth, Shaoyu Qiao, et al.
Pageof 148

Showing results (1431-1440 of 1,475) with videos related to

Sort By:
Pageof 148
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2005
Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study resultsDavid A Reardon, Gamal Akabani, R Edward Coleman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 1999
Irinotecan therapy in adults with recurrent or progressive malignant gliomaH S Friedman, W P Petros, A H Friedman, et al.
Oncotarget|April 12, 2014
Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomasPatrick J Killela, Christopher J Pirozzi, Patrick Healy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2002
Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomasDavid A Reardon, Gamal Akabani, R Edward Coleman, et al.
Neuro-Oncology|February 22, 2008
A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boostDavid A Reardon, Michael R Zalutsky, Gamal Akabani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 10, 2006
Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant gliomaDavid A Reardon, Jennifer A Quinn, James J Vredenburgh, et al.
Nature Genetics|June 2, 2014
Exome sequencing identifies somatic gain-of-function PPM1D mutations in brainstem gliomasLiwei Zhang, Lee H Chen, Hong Wan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 26, 2003
Phase II trial of gefitinib in recurrent glioblastomaJeremy N Rich, David A Reardon, Terry Peery, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 14, 2000
Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant gliomaH S Friedman, J Pluda, J A Quinn, et al.
Brain Communications|June 6, 2022
Intraoperative microseizure detection using a high-density micro-electrocorticography electrode arrayJames Sun, Katrina Barth, Shaoyu Qiao, et al.
Pageof 148